Compare IQ & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQ | ABUS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 839.5M |
| IPO Year | 2017 | 2008 |
| Metric | IQ | ABUS |
|---|---|---|
| Price | $1.01 | $4.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.91 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 5.5M | 1.8M |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $3.54 | $239.71 |
| P/E Ratio | ★ N/A | $5.20 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $0.98 | $3.04 |
| 52 Week High | $2.76 | $5.10 |
| Indicator | IQ | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 55.54 |
| Support Level | $0.98 | $4.15 |
| Resistance Level | $1.19 | $4.60 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 20.89 | 58.31 |
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.